MB&P Tools & Diagnostics

Pivotal Architecture Decision Grid: Choose the Evidence Architecture Before It Chooses Your Future

The pivotal architecture is not only a statistical choice. It determines what can be claimed, how regulators and payers will challenge the evidence, what follow-on evidence may be required and how much capital remains exposed if the assumptions fail.

The decision problem. Teams are naturally attracted to designs that look faster or smaller. The downstream cost may be hidden: narrower labels, confirmatory obligations, payer uncertainty, weaker partnering credibility or a second study that was never included in the original financing plan.

When this diagnostic is useful

Before an irreversible commitment

Use it before a protocol lock, pivotal-design decision, regulatory interaction, major vendor commitment, financing gate, partnering discussion or repeat-study decision.

When the team is not converging

Use it when different functions are giving individually reasonable answers that do not yet add up to one defensible development decision.

What to pressure-test

Comparator credibility
Causal question and estimand
Regulatory comfort and confirmatory burden
HTA and price risk
Label scope and differentiation
Timeline and execution complexity
Data dependency and external-control risk
Patient control exposure and ethical access
Financing runway and downside if assumptions fail

Red flags

Speed is the dominant argument for the preferred design.
The board has not compared the cost of a narrower label or delayed confirmatory evidence.
Payer evidence needs enter only after the regulatory design is fixed.
There is no predefined evidence that would cause the team to change architecture before FPI.

Why this matters to capital

A pivotal trial is one of the largest capital-allocation decisions in a biotech programme. The cheapest design is not necessarily the design with the lowest expected cost to value inflection.

What changes after a useful review

A useful diagnostic does not end with a score. It identifies the dominant uncertainty, distinguishes what is known from what is assumed, shows which decision is currently exposed and defines the smallest next action capable of changing that decision.

Illustrative outcome from selected work. In selected pivotal rare-disease/CNS work, aligning endpoints, estimands, FDA/EMA expectations, HTA logic and operational guardrails produced a submission-ready protocol package and reduced the risk of a statistically positive but commercially weak trial.

Download the one-page diagnostic

The downloadable version is intentionally concise. It is designed to structure an internal discussion and reveal where a programme-specific review may be warranted; the full professional working method is not published.

Download the Pivotal Architecture Decision Grid PDF

Related expertise

Clinical Development Strategy & Pivotal Trial Design From Strategy to Controlled Execution Results & case snapshots

Start with the decision, not the deliverable

Compare the architectures before the protocol, vendor plan and financing narrative become organisationally irreversible.

Start with a 20-minute Clinical Decision Diagnostic

Bring one live decision, the next hard milestone and the time available. The first conversation is designed to determine whether focused senior intervention can create material value.

Educational decision-support tool. It does not replace programme-specific medical, statistical, regulatory, operational, financial or legal review.